Trials / Active Not Recruiting
Active Not RecruitingNCT05700994
Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM)
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1,283 (actual)
- Sponsor
- Oregon Health and Science University · Academic / Other
- Sex
- All
- Age
- 18 Years – 105 Years
- Healthy volunteers
- Not accepted
Summary
The main goal of this study is to tests the effect of incentivizing achievement of self-identified, personal harm reduction goals (Contingency management or CM) compared with standard of care (peer harm reduction service with incentives for peer visits) to increase the reach and effectiveness of methamphetamine (MA) harm reduction services.
Detailed description
Using a hybrid type 1 effectiveness-implementation framework and stepped-wedge design, this study will randomize eighteen community-based peer harm reduction sites to provide contingency management incentives for achieving self-identified harm reduction goals set with peer specialists using a participant-driven harm reduction goal-setting process (e.g. completing overdose prevention and supply training, daily life goals, treatment and care goals, relationship and social support goals) versus standard of care contingency management (i.e. incentives for peer encounter attendance).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Peer Contingency Management | Participants allocated to peer-facilitated contingency management will receive incentives for achieving self-identified harm reduction goals set with peer specialists using a participant-driven harm reduction goal-setting process (e.g. completing overdose prevention and supply training, daily life goals, treatment and care goals, relationship and social support goals) |
| BEHAVIORAL | Standard of Care Contingency Management | Participants allocated to standard of care contingency management will receive incentives for peer encounters. |
Timeline
- Start date
- 2023-11-13
- Primary completion
- 2026-09-30
- Completion
- 2026-09-30
- First posted
- 2023-01-26
- Last updated
- 2026-01-14
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT05700994. Inclusion in this directory is not an endorsement.